Recommended Conferences for FATTY LIVER

FATTY LIVER

As per available reports about 14 Relevant Journals, 03 Conferences are presently dedicated exclusively to Fatty Liver and about 954 articles are being published on Fatty Liver.

Fatty liver also known as fatty liver disease (FLD) which is a reversible condition where large vacuoles of triglyceride fat accumulate in the liver cells by the process called steatosis. Fatty liver can also be considered as a single disease which occurs by excessive alcohol intake and without the effect of insulin resistance. Fatty liver disease mainly associated with alcohol or metabolic syndrome but can also occur due to metabolic, nutritional, drugs, and toxins.

Treatment of Hepatitis is on the cutting edge of medicine. Hepatitis B virus infection (HBV) has been recognized as a major health problem worldwide and Hepatitis C virus (HCV) infection is the most common chronic blood borne infection in the United States. Viral hepatitis treatment depends on how active the virus is in your body. Viral hepatitis is the most common cause of hepatitis worldwide. Other causes of non-viral hepatitis include alcoholic hepatitis and autoimmune hepatitis.

Fatty liver also known as fatty liver disease (FLD) which is a reversible condition where large vacuoles of triglyceride fat accumulate in the liver cells by the process called steatosis. Fatty liver can also be considered as a single disease which occurs by excessive alcohol intake and without the effect of insulin resistance.

Market Analysis:

More than 2 000 million people alive today have been infected with HBV at some time in their lives. Of these, about 350 million remain infected chronically and become carriers of the virus. Three quarters of the world’s population live in areas where there are high levels of infection. Every year there are over 4 million acute clinical cases of HBV, and about 25% of carriers, 1 million people a year, die from chronic active hepatitis, cirrhosis or primary liver cancer. High endemicity areas include sub-Saharan Africa, the Middle East, the central Asian Republics, and some countries in eastern Europe. In these areas, about 70 to 90% of the population becomes HBV-infected before the age of 40, and 8 to 20% of people are HBV carriers. In countries such as China, Senegal, and Thailand, infection rates are very high in infants, and continue through early childhood. At that stage the prevalence of HBsAg in serum may exceed 25%. HBV is well studied in Saudi Arabia where the prevalence in the general population is 4.25%. The genotype of the virus D predominates in the Middle East. The highest prevalence (17.5%) of HCV in the world was reported in Egypt. The pooled prevalence of HCV in haemodialysis patients is 16% in Iran, 56% in Saudi Arabia, 52% in Syria, and 34% in Sudan.